Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein
Joel B
JB
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards; D004317:Doxorubicin / Q000627:therapeutic use; D017277:Drug Approval / Q000458:organization & administration*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004317:Doxorubicin